2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Roberto Iacovelli, MD, PhD, discusses the key takeaways of the phase 2 ARIES trial in urothelial cancer.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Roberto Iacovelli, MD, PhD, medical oncologist, the Fondazione Policlinico Gemelli IRCCS, Rome, Italy, discusses the key takeaways of the phase 2 ARIES trial (NCT03891238) in urothelial cancer.
The ARIES trial evaluated first-line avelumab (Bavencio) in patients with metastatic and locally advanced urothelial cancer who were PD-L1 positive and unfit for cisplatin-based chemotherapy.
Findings from this study suggested avelumab demonstrated activity in urothelial cancer, Iacovelli says. Moreover, avelumab has a tolerable safety profile, Iacovelli adds.
Notably, patients with urothelial cancer who are ineligible for cisplatin-based chemotherapy tend to have a poor prognosis, and they are generally frailer, Iacovelli explains. These patients should be managed with immunotherapy and should be further studied in future clinical trials, Iacovelli concludes.
Related Content: